Richard R. Furman, M.D.

Medical Oncology



1.        Furman, RR, Z Asgary, JO Mascarhenas, HC Liou, EJ Schattner. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol. 164(4): 2200-2206, 2000.
2.        Leonard JP, M Coleman, JC Ketas, A Chadburn, S Ely, RR Furman, WA Wegener, HJ Hansen, H Ziccardi, M Eschenberg, U Gayko, A Cesano, DM Goldenberg. Phase I/II Trial of Epratuzumab (Humanized anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma. J Clin Oncol 21 (16):1-9, 2003.
3.        Damaj G, F Lefrere, R Delarue, B Varet, R Furman, O Hermine. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 17: 1914-1915, 2003.
4.        Furman RR, M Coleman, Leonard JP. Epratuzumab in non-Hodgkin’s lymphomas. Curr Treat Options Oncol. 5(4):283-288, 2004.
5.        Leonard JP, M Coleman, JC Ketas, A Chadburn, R Furman, MW Schuster, EJ Feldman, M Ashe, SJ Schuster, WA Wegener, HJ Hansen, H Ziccardi, M Eschenberg, U Gayko, SZ Fields, A Cesano, DM Goldenberg. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin’s lymphoma: phase I/II clinical trial results. Clin Cancer Res. 2004; 10(16):5327-5334.
6.        Leonard JP, M Coleman, J Ketas, M Ashe, JM Fiore, RR Furman, R Niesvizky, T Shore, A Chadburn, H Horne, J Kovacs, CL Ding, WA Wegener, ID Horak, DM Goldenberg. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol. 2005; 23(22):5044-5051.
7.        Leonard JP, RR Furman, J Ruan, M Coleman. New Developments in immunotherapy for non-Hodgkin’s lymphoma. Curr Oncol Rep. 2005; 7(5):364-371.
8.        Leonard JP, M Coleman, L Kostakoglu, A Chadburn, E Cesarman, RR Furman, MW Schuster, R Niesvizky, D Muss, J Fiore, S Kroll, G Tidmarsh, S Vallabhajosula, SJ Goldsmith. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I-131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005; 23(24):5696-5704.
9.        Dosik AD, Coleman M, Kostakoglu L, Furman RR, Fiore JM, Muss D, Niesvizky R, Shore T, Schuster MW, Stewart P, Vallabhajosula S, Goldsmith SJ, Leonard JP. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin’s lymphoma. Cancer. 2006; 106(3): 616-622.
10.     Leonard JP, Furman RR, Coleman M. Proteasome inhibition with bortezomib: A new therapeutic strategy for non-Hodgkin’s lymphoma. Int J. Cancer. 2006; 119(5): 971-979.
11.     Leonard JP, RR Furman, M Coleman. Targeting Proteasome Inhibition in Lymphoma and Other Lymphoproliferative Disorders. Am J. of Oncology Rev. 2006; 5(5) S6: 11-14.
12.     Furman RR, M Coleman, D Muss, JP Leonard. Monoclonal Antibodies in the Treatment of non-Hodgkin’s lymphoma. Cancer Treatment and Research. 221-250. ST Rosen, series editor, Springer, New York, 2006.
13.     Kostakoglu L, SJ Goldsmith, JP Leonard, P Christos, RR Furman, T Atasever, A Chandramouly, S Verma, P Kothari, M Coleman. PDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin’s disease. Cancer. 2006; 107:2678-2687.
14.     Mones JV, M Coleman, L Kostakoglu, RR Furman, A Chadburn, TB Shore, D Muss, P Stewart, S Kroll, S Vallabhajosula, SJ Goldsmith, JP Leonard. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin’s lymphoma (NHL) and extensive bone marrow involvement. Leukemia & Lymphoma. 2007; 48(2):342-348.
15.     Roboz GJ, JM Bennett, M Coleman, EK Ritchie, RR Furman, A Rossi, K Jhaveri, EJ Feldman, JP Leonard. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin’s lymphoma. Leukemia Research. 2007; 31: 1149-1152.
16.     Furman RR, JP Leonard. Immunotherapy of B-cell malignancies: first MABs, now SMIPs. Blood. 2007; 110: 2218.
17.     Pulte D, KE Olson, MJ Broekman, N Islam, HS Ballard, RR Furman, AE Olson, AJ Marcus. CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia. J Transl Med. 2007; 4:23-32.
18.     Martin P, RR Furman, M Coleman, JP Leonard. Phase I to III trials of anti-B cell therapy in non-Hodgkin’s lymphoma. Clin Cancer Res. 2007; 13(18 Suppl): 5636s-5642s.
19.     Furman RR, D Hoelzer. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies. Semin Oncol. 2007;34(6 Suppl 5):S29-34.
20.     Krause PJ, BE Gewurz, D Hill, FM Marty, E Vannier, IM Foppa, RR Furman, E Neuhaus, G Skowron, S Gupta, C McCalla, EL Pesanti, M Young, D Heiman, G Hsue, JA Gelfand, GP Wormser, J Dickason, FJ Bia, B Hartman, SR Telford 3rd, D Christianson, K Dardick, M Coleman, JE Girotto, A Spielman. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis. 2008; 46(3): 370-376.
21.     Blinder VS, A Chadburn, RR Furman, S Mathew, JP Leonard. Improving outcomes for patients with Burkitt lymphoma and HIV. AIDS Patient Care and STDs 2008; 22(3): 175-187.
22.     Coleman M, P Martin, J Ruan, R Furman, R Niesvizky, R Elstrom, P George, J Leonard, T Kaufmann. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leukemia & Lymphoma 2008; 49(3): 447-450.
23.     Coleman M, P Martin, J Ruan, R Furman, R Niesvizky, R Elstrom, P George, TP Kaufman, JP Leonard. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008; 112(10): 2228-2232.
24.     Martin P, A Chadburn, P Christos, R Furman, J Ruan, MA Joyce, E Fusco, P Glynn, R Elstrom, R Niesvizky, EJ Feldman, TB Shore, MW Schuster, S Ely, DM Knowles, S Chen-Kiang, M Coleman, JP Leonard. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol. 2008; 19(7): 1327-1330.
25.     Martin P, RR Furman, J Ruan, R Elstrom, J Barrientos, R Niesvizky, M Coleman, JP Leonard. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin’s lymphoma. Semin Hematol. 2008; 45: 126-132.
26.     Rutherford SC, B Andemariam, SM Philips, RL Elstrom, A Chadburn, RR Furman, R Niesvizky, P Martin, TJ Fahey, M Coleman, SJ Goldsmith, JP Leonard. FDG-PET in prediction of splenectomy findings in patients with known or suspect lymphoma. Leuk Lymphoma. 2008; 49(4): 719-726.
27.     Leonard JP, P Martin, J Ruan, R Elstrom, J Barrientos, M Coleman, RR Furman. New monoclonal antibodies for non-Hodgkin’s lymphoma. Ann Oncol. 2008; 19 Suppl 4: iv60-62.
28.     Paoluzzi L, M Gonen, G Bhagat, RR Furman, JR Gardner, L Scotto, VD Gueorguiev, ML Heaney, K Manova, OA O’Connor. The BH3-only mimetic ABT-737 synergizes the anti-neoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood. 2008.

Back to topBack To Top